Abstract Body

Background

Point-of-care medication adherence tests can be used in clinical trials and routine care to monitor and improve HIV health outcomes. Urine tenofovir lateral flow assays (LFAs) are rapid and inexpensive but cannot distinguish between recent (<1 week) and long-term (1-3 month) adherence. The REverse transcriptase ACTivity (REACT) assay measures tenofovir diphosphate (TFV-DP), a metabolite that indicates long-term oral PrEP/ART adherence, based on the drug’s inhibition of DNA synthesis by HIV reverse transcriptase (RT) enzyme. We recently demonstrated that REACT with CRISPR (REACTR) can provide TFV-DP concentration levels with lateral flow readout. Here we demonstrate a pilot validation of REACTR LFA with clinical samples.

Methods

We combined DNA templates, nucleotides, HIV-RT, biotin-FITC reporters, CRISPR RNA, Cas12a, and Thermolabile Proteinase K with 30 rehydrated dried blood spots from the Women TDF-FTC Benchmark Study (NCT05057858). We incubated REACTR assays at 37°C for 45 minutes and visualized reaction products on commercially available LFA strips (Abingdon Health PCRD Flex) immersed in reaction tubes for 10 minutes. The test line of the LFA strip detects the presence of uncleaved CRISPR reporters, so we included two “no enzyme” controls per DBS sample tested to determine the maximum signal achievable. We scanned the LFAs to quantify the test line intensity and calculated signal-to-background ratios (SBR). REACTR results were compared with 70% methanol:30% water extraction LC-MS TFV-DP measurements.

Results

No-enzyme controls had an average SBR of 4.64 ± 0.39 and a coefficient of variation of 8.37% which indicates low inter-strip variability. SBR values correlated with LC-MS TFV-DP concentrations for DBS samples (r = 0.8732, n=30) (Fig. A). The assay had high sensitivity (100.0%) and specificity (100.0%) in distinguishing samples above the 700 fmol/punch TFV-DP threshold (SBR = 2.675) for adequate PrEP adherence (≥ 4 doses/week) (Fig. B).

Conclusions

REACTR with LFA readout may be suitable for use in resource-constrained settings for rapid adherence measurement and as a triage tool prior to drug resistance screening for people with virologic failure. Ongoing work is focused on streamlining sample preparation, integrating the assay into a user-friendly form factor, and validating with clinical samples from people living with HIV.

Table or Figure